Federal Register / Vol. 79, No. 239 / Friday, December 12, 2014 / Notices 73907 

Central District of California, Case No. 

CR 99–673, for a violation of 18 U.S.C. 

371. 

By letter dated June 6, 2012, ATF 

granted relief to Northrop Grumman 

Guidance and Electronics Company, 

Inc., a wholly owned subsidiary of NGC, 

resulting from its own prohibiting 

convictions, but took no action on relief 

to the non-surviving entities because 

they no longer exist. See 77 FR 58150. 

Nonetheless, because NGSC merged 

with and succeeded the assets and 

operations of the non-surviving entities, 

ATF subsequently determined that 

NGSC, as their successor, is eligible for 

relief. 

Pursuant to 18 U.S.C. 925(c), on 

September 23, 2014, NGSC, a wholly 

owned subsidiary of NGC, as successor 

to TRW Electronic Products, Inc., TRW, 

Inc., and Litton Applied Technology 

Division, was granted relief by ATF 

from the disabilities imposed by Federal 

law, 18 U.S.C. 922(g)(1), with respect to 

the acquisition, receipt, transfer, 

shipment, transportation, or possession 

of firearms and ammunition as a result 

of these convictions of the nonsurviving entities. It has been 

established to ATF’s satisfaction that the 

circumstances regarding NGSC’s 

disabilities and its record and 

reputation are such that the NGSC will 

not be likely to act in a manner 

dangerous to public safety, and that the 

granting of the relief would not be 

contrary to the public interest. 

B. Todd Jones, 

Director. 

[FR Doc. 2014–29236 Filed 12–11–14; 8:45 am] 

BILLING CODE 4410–FY–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–405] 

Electronic Prescriptions for Controlled 

Substances: Notice of Approved 

Certification Process 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: Notice of approved certification 

process. 

SUMMARY: The Drug Enforcement 

Administration is announcing one new 

DEA-approved certification process for 

providers of Electronic Prescriptions for 

Controlled Substances applications. 

Certifying organizations with an 

approved certification process are 

posted on the Drug Enforcement 

Administration’s Web site upon 

approval. 

FOR FURTHER INFORMATION CONTACT: 

Imelda L. Paredes, Office of Diversion 

Control, Drug Enforcement 

Administration; Mailing Address: 8701 

Morrissette Drive, Springfield, Virginia 

22152, Telephone: (202) 598–6812. 

SUPPLEMENTARY INFORMATION: 

Legal Authority 

The Drug Enforcement 

Administration (DEA) implements and 

enforces titles II and III of the 

Comprehensive Drug Abuse Prevention 

and Control Act of 1970, as amended. 

Titles II and III are referred to as the 

‘‘Controlled Substances Act’’ and the 

‘‘Controlled Substances Import and 

Export Act,’’ respectively, and are 

collectively referred to as the 

‘‘Controlled Substances Act’’ or the 

‘‘CSA’’ for the purpose of this notice. 21 

U.S.C. 801–971. The DEA publishes the 

implementing regulations for these 

statutes in title 21 of the Code of Federal 

Regulations (CFR), chapter II. The CSA 

and its implementing regulations are 

designed to prevent, detect, and 

eliminate the diversion of controlled 

substances and listed chemicals into the 

illicit market while providing for the 

legitimate medical, scientific, research, 

and industrial needs of the United 

States. Controlled substances have the 

potential for abuse and dependence and 

are controlled to protect the public 

health and safety. 

The CSA and DEA’s implementing 

regulations establish the legal 

requirements for possessing and 

dispensing controlled substances, 

including the issuance of a prescription 

for a legitimate medical purpose by a 

practitioner acting in the usual course of 

professional practice. The responsibility 

for the proper prescribing and 

dispensing of controlled substances is 

upon the prescribing practitioner, but a 

corresponding responsibility rests with 

the pharmacist who fills the 

prescription. 21 CFR 1306.04(a). The 

prescription provides a record of the 

actual dispensing of the controlled 

substance to the ultimate user (the 

patient) and, therefore, is critical to 

documenting that controlled substances 

held by a pharmacy have been 

dispensed. The maintenance of 

complete and accurate records is an 

essential part of the closed system of 

distribution established by Congress. 

Electronic Prescriptions for Controlled 

Substances 

Historically, where Federal law 

required that a prescription for a 

controlled substance be issued in 

writing, that requirement could only be 

satisfied through the issuance of a paper 

prescription. Given advancements in 

technology and security capabilities for 

electronic applications, the DEA 

amended its regulations to provide 

practitioners with the option of issuing 

electronic prescriptions for controlled 

substances in lieu of paper 

prescriptions. The DEA’s interim final 

rule for Electronic Prescriptions for 

Controlled Substances was published on 

March 31, 2010, at 75 FR 16236–16319, 

and became effective on June 1, 2010. 

Update 

Certifying Organization With a 

Certification Process Approved by the 

DEA Pursuant to 21 CFR 1311.300(e) 

The interim final rule and the DEA’s 

Electronic Prescriptions for Controlled 

Substances Clarification (76 FR 64813) 

provide that, as an alternative to the 

third-party audit requirements of 21 

CFR 1311.300(a) through (d), an 

electronic prescription or pharmacy 

application may be verified and 

certified as meeting the requirements of 

21 CFR part 1311 by a certifying 

organization whose certification process 

has been approved by the DEA. The 

preamble to the interim final rule 

further indicated that, once a certifying 

organization’s certification process has 

been approved by the DEA in 

accordance with 21 CFR 1311.300(e), 

such information will be posted on the 

DEA’s Web site. 75 FR 16243 (March 31, 

2010). On December 3, 2014, the DEA 

approved the certification process 

developed by Electronic Healthcare 

Network Accreditation Commission. 

Relevant information has been posted 

on the DEA’s Web site at: http://www.

DEAdiversion.usdoj.gov. 

Dated: December 3, 2014. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2014–29118 Filed 12–11–14; 8:45 am] 

BILLING CODE 4410–09–P 

NUCLEAR REGULATORY 

COMMISSION 

[Docket No. 72–0008, NRC–2011–0085] 

Exelon Generation Corporation, LLC; 

Calvert Cliffs Independent Spent Fuel 

Storage Installation 

AGENCY: Nuclear Regulatory 

Commission. 

ACTION: License amendment application; 

notice of docketing; opportunity to 

request a hearing and to petition for 

leave to intervene; and order. 

SUMMARY: The U.S. Nuclear Regulatory 

Commission (NRC) has docketed a 

license amendment application from 

mstockstill on DSK4VPTVN1PROD with NOTICES